Early-stage biotech NeuroScientific Biopharmaceuticals has delivered real-world promise for those living with chronic Crohn’s disease following recent findings from its StemSmart cell therapy. Prescribed under Australia’s Special Access Scheme, the results showed a strong clinical response in some of Crohn’s disease’s toughest patients, giving the company valuable validation, sharper trial design and a clearer pathway into a multi-billion-dollar global market.
In the high-octane world of biotech, nothing speaks louder than results in real patients.
And that’s exactly what NeuroScientific Biopharmaceuticals appears to have delivered, with fresh data showing its StemSmart stem cell therapy is making a meaningful difference for people living with the debilitating bowel condition, fistulising Crohn’s disease.
Judging by today’s response, the market agrees with the company’s shares up as much as 52 per cent to 17.5c on the highest turnover in more than six months.
The company’s innovative StemSmart therapy uses a specialised class of mesenchymal stem cells (MSC), prepared as a simple intravenous infusion. These cells are harvested from adult donor bone marrow and then run through a patented refinement process designed to dial up their therapeutic punch and improve clinical outcomes.
Better still, mesenchymal stem cells are universal donor cells, meaning no donor-recipient matching and no waiting lists. In practical terms, StemSmart is shaping up as a genuine off-the-shelf cell therapy.
Under Australia’s Special Access Scheme, patients who have exhausted conventional treatment options can apply for case-by-case access to new and unapproved therapies. Through this pathway, four people with the debilitating bowel condition were put forward by their clinicians to receive Neuroscientific’s StemSmart treatment.
The results were striking. Despite Crohn’s disease often being severe and stubbornly resistant to treatment, three of the four patients achieved a successful clinical response. At the same time, the fourth recorded a partial response with ongoing improvement.
NeuroScientific hasn’t wasted any time celebrating the early win – and with good reason. A clinical response in this setting is hard-earned, defined as closing at least half of existing fistula openings or slashing discharge by 50 per cent or more. For people living with chronic pain, infection and repeat surgery, that sort of turnaround is potentially life-changing.
Adding extra weight to the outcome, these treatments played out in the real world, where advanced disease doesn’t follow a script, rather than in a sanitised lab trial engineered for perfect data. According to the company, that gritty clinical setting has given the results far more bite, offering a clear window into how StemSmart might perform under everyday conditions.
Management says the outcome is more than just a tick for the StemSmart platform. It also vindicates the company’s $5.1 million move last June to snap up unlisted Perth-based stem cell specialist Isopogen, the original owner of the intellectual property behind the therapy.
NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: “These treatment results provide critical validation of the StemSmart MSC platform in presenting a potential therapeutic solution to patients with debilitating fistulising Crohn’s. This data, along with our previous clinical trial results in refractory Crohn’s disease, provides a strong foundation for our commercialisation plans for StemSmart moving forward.”
NeuroScientific Biopharmaceuticals chief medical officer Dr Cathy Cole added: “The response rate to StemSmart MSC treatment seen in these patients in a real-world setting is exceptional and offers hope for clinical recovery when there was previously little.”
With strong, early signs of validation now in hand, NeuroScientific says it's shifting its focus to the next phase of execution. Encouraging signals from earlier phase two work in refractory Crohn’s disease have already flagged strong efficacy and safety, and the latest real-world data only strengthens that case.
The company plans to fold these insights directly into the design of its next round of clinical trials, pencilled in for the second half of this year. Behind the scenes, the heavy lifting has already begun, with manufacturing scale-up, regulatory planning and trial development all moving in parallel to keep momentum building.
While Crohn’s disease alone represents a global market worth about US$13 billion, NeuroScientific believes its StemSmart platform has far wider potential. The company sees the technology extending into broader anti-inflammatory and immune-modulating applications, with possible pathways into organ transplant tolerance, lung inflammatory diseases and graft-versus-host disease.
In a sector where promise often runs well ahead of proof, NeuroScientific appears to be closing that gap. Real-world results, a clear clinical pathway and a platform technology with multiple shots on goal are now lining up.
If the company can carry this momentum into its next round of trials, StemSmart could quickly shift from an encouraging experiment into a top-notch biotech growth story.
Is your ASX-listed company doing something interesting? Contact: matt.birney@businessnews.com.au
